The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: 0.00 (0.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.00
Low: 0.00
Prev. Close: 0.10
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence and Product Supply Agreement with Tristel

23 Mar 2020 07:00

RNS Number : 1185H
Byotrol PLC
23 March 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

Know-How Licence and Product Supply Agreement with Tristel plc

 

 

Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.

 

The Agreement relates to three specific technologies

 

1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and

2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and

3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". 

The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"

 

 

Enquiries:

 

Byotrol plc

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRJTMMTMTMTTJM
Date   Source Headline
2nd Apr 202011:05 amRNSSecond Price Monitoring Extn
2nd Apr 202011:00 amRNSPrice Monitoring Extension
24th Mar 20209:05 amRNSSecond Price Monitoring Extn
24th Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:01 amRNSTrading Update
23rd Mar 20207:00 amRNSLicence and Product Supply Agreement with Tristel
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20202:05 pmRNSSecond Price Monitoring Extn
13th Mar 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
28th Feb 20204:15 pmRNSHolding(s) in Company
30th Jan 20205:00 pmRNSDirector/PDMR Shareholding
30th Jan 20208:00 amRNSAcceleration of earn-out relating to Medimark
19th Dec 20197:00 amRNSInterim Results
14th Nov 201912:30 pmRNSResult of AGM
13th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20192:54 pmRNSHolding(s) in Company
11th Oct 20193:00 pmRNSRestoration - Byotrol Plc
11th Oct 20193:00 pmRNSPosting of Accounts, Notice of AGM and Restoration
1st Oct 20193:50 pmRNSHolding(s) in Company
1st Oct 20197:30 amRNSSuspension - BYOTROL PLC
30th Sep 201912:01 pmRNSPublication of accounts and temporary suspension
30th Sep 201912:00 pmRNSUnaudited Preliminary Results to 31 March 2019
25th Sep 20197:00 amRNSNotice of Results
3rd Sep 20199:08 amRNSNotice of Results
28th May 20197:00 amRNSAppointment of CFO & Award of Options
9th May 20197:00 amRNSTrading Update
15th Apr 201911:58 amRNSHolding(s) in Company
28th Feb 20197:00 amRNSEPA Approval and Target Roll-Out
31st Jan 20199:14 amRNSHolding(s) in Company
29th Jan 20197:00 amRNSAppointment of New Director & Award of Options
31st Dec 20187:00 amRNSGrant of Options
21st Dec 20181:41 pmRNSHolding(s) in Company
21st Dec 20181:41 pmRNSHolding(s) in Company
20th Dec 201812:07 pmRNSDirector Dealings
18th Dec 20187:00 amRNSInterim Results
14th Nov 201810:35 amRNSHolding(s) in Company
13th Nov 20184:00 pmRNSHolding(s) in Company
13th Nov 201811:20 amRNSDirector/PDMR Shareholding
12th Nov 20185:05 pmRNSHolding(s) in Company
21st Sep 20184:00 pmRNSResult of AGM
4th Sep 201811:15 amRNSPosting of Annual Report and Notice of AGM
3rd Sep 20184:48 pmRNSHolding(s) in Company
3rd Sep 20184:12 pmRNSHolding(s) in Company
24th Aug 201812:01 pmRNSDirector Dealing
24th Aug 20187:00 amRNSDirector Dealing
23rd Aug 201811:31 amRNSAcquisition of Medimark Scientific Limited
23rd Aug 201811:30 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.